Exer-Rest Technology Presentation at the 2009 European Society of Cardiology Congress is Highly Effective in Treatment of Patients with Coronary Artery Disease, Angina and Reduced Cardiac Function

MIAMI--(BUSINESS WIRE)--Marvin A Sackner, M.D., Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that Drs. Miyamoto, Fujita and others from Osaka and Kyoto, Japan presented a paper entitled “Novel treatment with whole body periodic acceleration with a horizontal motion platform improves exercise capacity, myocardial ischemia and left ventricular function” at the European Society of Cardiology (ESC) Congress in Barcelona on September 1, 2009. The Exer-Rest^® patented technology was utilized to apply non-invasive whole body periodic acceleration [WBPA] for 45 minutes a day, 5 days a week for four weeks, a total of 20 treatments. A small dose of intravenous heparin was administered 10 to 20 minutes prior to each WBPA treatment. Thirteen patients, mean age 69 years, with advanced coronary artery disease, chronic effort angina and reduced cardiac function as measured by an ejection fraction that averaged 35% constituted the treatment group. Another 13 patients with the same characteristics, mean age 66 years, remained sedentary throughout a four week period as a control group.

“such improvements have never been reported with exercise training programs in coronary artery disease patients and perhaps WBPA might be better than exercise for this situation although confirmation is needed in a larger group of patients.”

Drs. Miyamoto and Fujita reported that they performed the following tests in the treated patients prior to WBPA and after its completion four weeks later: Bruce protocol exercise stress test with electrocardiography, echocardiography, and nuclear cardiac scanning. They obtained the same tests in the control patients who showed no changes after four weeks compared to baseline values. They found startling benefits in all tests in the WBPA treated patients. There was improvement in time of exercise of 2.54 minutes over baseline before reaching the established end-point of cardiac exercise stress testing, improved cardiac function as reflected by increase of ejection fraction, and, remarkable diminution in heart volumes as well as marked reduction in areas of inadequate blood flow to the heart wall at rest and after stress.

Dr. Miyamoto commented at his presentation during the ECS Congress that “such improvements have never been reported with exercise training programs in coronary artery disease patients and perhaps WBPA might be better than exercise for this situation although confirmation is needed in a larger group of patients.”

On September 11, 2009, Dr. Sackner presented at the 3^rd International Meeting on Rehabilitation in Rome a paper entitled, “Cardiopulmonary Effects of Low-Frequency, Low-Intensity Vibration,” in which he commented on Drs. Miyamoto and Fujita’s presentation at the ECS Congress. He reviewed 12 anti-angina drug trials carried out over 2 to 12 weeks that used the Bruce protocol stress test as an outcome measure for efficacy. The prolongation of exercise time reported by Drs. Miyamoto and Fujita exceeded every one of the drugs tested. Sackner further pointed out that after damage from coronary artery disease, the heart initially enlarges to compensate for the poor function of the damaged area. However, over time, enlargement progresses and leads to chronic heart failure. In this situation, it is important to introduce measures to reduce cardiac enlargement, a process called “left ventricular reverse remodeling.” WBPA reversed cardiac enlargement to a much greater extent than has been previously observed with standard drugs for heart failure. Dr. Sackner concluded that the effectiveness of WBPA in reverse remodeling probably relates to stimulating cardiac endothelial nitric oxide synthase (eNOS) activity with subsequent increase of nitric oxide in heart muscle as reported in rats by Wu and associates in the August issue of “Nitric Oxide.”

Steven Mrha, Chief Operating Officer of NIMS, stated that “the demonstration of marked improvement of heart function in patients with angina and impaired cardiac function is consistent with the intended use of Exer-Rest^® as a means to aid in the improvement of circulation.” He added that “it has been reported that about 10 percent of people over age 75 suffer from heart failure related to impaired cardiac function and the total cost for treatment of heart failure exceeds $38 billion dollars annually. Heart failure patients are greatly affected by this condition, having to deal with limitations on their breathing, mobility and their general quality of life.”

Exer-Rest^® is designed to be used without need for third party assistance and can be installed in the home, clinics, wellness centers, assisted living centers, nursing homes and hospitals.” Mrha added: “demonstration centers have been set-up in Miami, FL, Clifton, NJ, Beverly Hills, CA, Eau Claire, WI and Toronto, Canada where both healthcare professionals and private individuals can experience the benefits of this novel, new technology.”

Safe Harbor Statement: This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.